QUÉBEC CITY, May 11, 2015
/PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS)
(TSX: AEZ) (the "Company") announces the results of the
vote on directors held at its 2015 Shareholders' meeting on May
8, 2015. Each of the director nominees proposed by management
for election was elected as director, without a vote by ballot
being conducted. The Company received proxies with regard to voting
on the six directors nominated for election as set forth in the
table below:
|
Name of
Nominee
|
Votes
For
|
%
|
Votes
Withheld
|
%
|
|
Marcel
Aubut
|
18,128,464
|
94.07
|
1,141,916
|
5.93
|
|
David A.
Dodd
|
18,080,446
|
93.83
|
1,189,934
|
6.17
|
|
Carolyn
Egbert
|
18,154,579
|
94.21
|
1,115,801
|
5.79
|
|
Juergen
Ernst
|
17,913,295
|
92.96
|
1,357,085
|
7.04
|
|
Pierre
Lapalme
|
18,123,537
|
94.05
|
1,146,843
|
5.95
|
|
Gérard
Limoges
|
18,149,458
|
94.18
|
1,120,922
|
5.82
|
All other matters at the shareholders' meeting were also
approved by shareholders.
About Aeterna Zentaris Inc.
Aeterna Zentaris is a specialty biopharmaceutical company
engaged in developing and commercializing novel treatments in
oncology, endocrinology and women's health. For more information,
visit www.aezsinc.com.
Forward-Looking Statements
This press release contains forward-looking statements made
pursuant to the safe harbor provisions of the US Securities
Litigation Reform Act of 1995. Forward-looking statements involve
known and unknown risks and uncertainties that could cause Aeterna
Zentaris's actual results to differ materially from those in the
forward-looking statements. Such risks and uncertainties include,
among others, the availability of funds and resources to pursue
R&D projects and clinical trials, the successful and timely
completion of clinical studies, the risk that safety and efficacy
data from any of our Phase 3 trials may not coincide with the data
analyses from previously reported Phase 1 and/or Phase 2 clinical
trials, the ability of Aeterna Zentaris to efficiently
commercialize one or more of its products or product candidates,
the ability of Aeterna Zentaris to take advantage of business
opportunities in the pharmaceutical industry, uncertainties related
to the regulatory process, the ability to protect our intellectual
property, the potential of liability arising from shareholder
lawsuits and general changes in economic conditions. Investors
should consult Aeterna Zentaris' quarterly and annual filings with
the Canadian and US securities commissions for additional
information on risks and uncertainties relating to forward-looking
statements. Investors are cautioned not to place undue reliance on
these forward-looking statements. Aeterna Zentaris does not
undertake to update these forward-looking statements. We disclaim
any obligation to update any such factors or to publicly announce
the result of any revisions to any of the forward-looking
statements contained herein to reflect future results, events or
developments, unless required to do so by a governmental authority
or by applicable law.
SOURCE Aeterna Zentaris Inc.